CNS Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
CNSP CNS Pharmaceuticals Inc
SMTC Semtech Corp
EU enCore Energy Corp
CJET Chijet Motor Co Inc
LAKE Lakeland Industries Inc
JWEL Jowell Global Ltd
SMAR Smartsheet Inc
FOXA Fox Corp
SCVFF Scotch Creek Ventures Inc
VEDU Visionary Education Technology Holdings Group Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Price
Delayed
$2.59
Day's Change
-0.09 (-3.36%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.72
Day's Low
2.48
Volume
(Light)

Today's volume of 88,433 shares is on pace to be much lighter than CNSP's 10-day average volume of 1,263,378 shares.

88,433

Marathon Shareholder Notice

9:37 pm ET March 20, 2023 (Newsfile) Print

New York, New York--(Newsfile Corp. - March 20, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Marathon Digital Holdings Inc. ("Marathon" or the "Company") (NASDAQ: MARA).

If you suffered losses exceeding $50,000 investing in Marathon stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may alsoclick here for additional information: www.faruqilaw.com/MARA.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/6455/159141_b7fec02ee4f48a40_001full.jpg



There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.

On February 28, 2023, Marathon issued press release announcing "that it has cancelled its webcast and conference call for the fourth quarter and fiscal year 2022, initially scheduled for today, February 28, 2023, at 4:30 p.m. Eastern time, and will postpone the publication of its corresponding financial results." The company also disclosed that on Feb. 22, Marathon received a comment letter from the Corporation Finance Staff of the U.S. Securities and Exchange Commission relating to issues including accounting matters.

The audit committee of Marathon's board concluded that audited financial statements in its Form 10-K for 2021 and unaudited statements for interim periods in several quarterly reports should no longer be relied upon.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/159141

comtex tracking

COMTEX_427114752/2523/2023-03-20T21:37:19

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.